Andreas Norlin
Chief Tech/Sci/R&D Officer at ASCELIA PHARMA AB
Net worth: 10 650 $ as of 2024-03-30
Profile
Andreas L.
Norlin is the founder of Xkout Bioscience AB.
He is currently the Director at ApoGlyx AB and the Chief Scientific Officer at Ascelia Pharma AB.
Dr. Norlin has a graduate and doctorate degree from the University of Lund.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ASCELIA PHARMA AB
0.04% | 2023-07-12 | 12,364 ( 0.04% ) | 10 650 $ | 2024-03-30 |
Andreas Norlin active positions
| Companies | Position | Start |
|---|---|---|
| ASCELIA PHARMA AB | Chief Tech/Sci/R&D Officer | 2019-12-31 |
ApoGlyx AB
 ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Director/Board Member | - |
Former positions of Andreas Norlin
| Companies | Position | End |
|---|---|---|
| Xkout Bioscience AB | Founder | - |
Training of Andreas Norlin
| University of Lund | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ASCELIA PHARMA AB | Health Technology |
| Private companies | 2 |
|---|---|
ApoGlyx AB
ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Health Technology |
| Xkout Bioscience AB |
- Stock Market
- Insiders
- Andreas Norlin
